NOVEL OCTAHYDROPYRIDOQUINAZOLINE DERIVATIVE, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USES FOR SAID DERIVATIVE AND COMPOSITION
申请人:Kissei Pharmaceutical Co., Ltd.
公开号:EP2930175A1
公开(公告)日:2015-10-14
[Problem] To provide a novel compound that exhibits an agonistic effect on dopamine D2 receptors.
[Solution] The present invention provides a compound represented by the general formula (I):
in which R1 is C1-6 alkyl or the like; R2 is hydrogen or the like; R3 and R4 are each hydrogen, C1-6 alkyl, R10R11N-C1-6 alkyl, aralkyl, or the like; R5 and R6 are hydrogen or the like; and R7 is hydrogen or the like, or a pharmaceutically acceptable salt thereof, a pharmaceutical compositions containing same and uses for said compound/salt and composition. The compounds of the present invention exhibit potent dopamine D2 receptor simulating activities and thus are useful as a treating or preventing agent for Parkinson's disease and the like.
[问题]提供一种对多巴胺 D2 受体具有激动作用的新型化合物。
[解决方案] 本发明提供一种由通式(I)表示的化合物:
其中 R1 是 C1-6 烷基或类似物;R2 是氢或类似物;R3 和 R4 分别是氢、C1-6 烷基、R10R11N-C1-6 烷基、芳烷基或类似物;R5 和 R6 是氢或类似物;以及 R7 是氢或类似物,或其药学上可接受的盐、含有相同物质的药物组合物以及所述化合物/盐和组合物的用途。本发明的化合物具有强效的多巴胺 D2 受体模拟活性,因此可用作帕金森病等的治疗或预防剂。